Progress in the investigation of cardiovascular protective effects of DPP-4 inhibitors
10.3760/cma.j.issn.1000-6699.2014.03.021
- VernacularTitle:二肽基肽酶-4抑制剂心血管保护作用的研究进展
- Author:
Ying RU
;
An REN
;
Shandong YE
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Glucagon-like peptide-1;
Dipeptydil-peptidase-4;
Sitagliptin
- From:
Chinese Journal of Endocrinology and Metabolism
2014;30(3):258-260
- CountryChina
- Language:Chinese
-
Abstract:
Dipeptydil-peptidase-4 (DPP-4) inhibitors are designed as oral anti-hyperglycemic drugs for the treatment of type 2 diabetes owing to their effects on the incretin system through sparing incretin hormones including glucagon-like peptide-1 (GLP-1) from rapid degradation by DPP-4.It has been shown that GLP-1 signaling may exert beneficial effects on cardiovascular system.In addition to GLP-1,DPP-4 physiologically cleaves cytokines,chemokines,and neuropeptides involved in inflammation,immunity,and vascular function.It means that DPP-4 inhibitors hold promise for cardiovascular protection independent of GLP-1.And its modulation of endothelial progenitor cells,infiammatory pathway,ischemic response,and lipid metabolism emerges as the major cardiovascular target of DPP-4 inhibitors.
